Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Shanghai Fosun Pharmaceutical Group Co. Ltd. (复星医药)
Headquarters: Shanghai, China
Website: https://www.fosunpharma.com/e...
Year Founded: 1994
Status: Public
Industry Sector: HealthTechnology
CEO: De Yong Wen, MBA
Number Of Employees: 40,557
Enterprise Value: $13,641,205,302
PE Ratio: 22.8
Exchange/Ticker 1: Shanghai:600196
Exchange/Ticker 2: HKEX:2196
Latest Market Cap: $8,619,535,062
BioCentury | Apr 7, 2025
Data Byte
Hong Kong stocks plunge. More tariffs loom
Previously a bright spot in 2025 markets, Hong Kong stocks take a sharp downturn
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | Sep 27, 2023
Deals
Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front
The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape
BioCentury | Sep 9, 2023
Deals
CAR T collaborations: the next cross-border deal trend?
BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
BioCentury | Sep 9, 2023
Discovery & Translation
Targeting IRE1 in KRASi-resistant tumors; plus AZ’s Cas9 variant and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 25, 2023
Data Byte
BioNTech strikes another deal with Chinese biotech, third YTD
After string of deals granting access to its COVID-19 vaccine in Asia, the German biotech has begun in-licensing cancer tech from the region
BioCentury | Dec 24, 2022
BioCentury Commentary
Noisemakers and newsmakers of 2022, and hot takes for 2023
BioCentury’s analysts look back at a year when industry took some slings and arrows but delivered breakthroughs, and predict what’ll be hot in 2023
BioCentury | Aug 11, 2022
Finance
Aug. 10 Quick Takes: Karuna parlays data into year’s largest follow-on, at $750M
Plus Disc finds public path, Insilico refuels for growth and updates from BMS, Prellis and more
BioCentury | Apr 23, 2022
Product Development
How biotechs are coping with lockdown in Shanghai
Staff at whitelisted companies living at their workplaces
BioCentury | Feb 16, 2022
Finance
‘Green shoots’ in China lift Hong Kong biotechs, but U.S. rally fizzles
Approval of Pfizer antiviral drives gains in China stocks
Items per page:
1 - 10 of 130